Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Helsinki, Finland; Research Program Unit, Immunobiology, University of Helsinki, Helsinki, Finland.
Department of Vaccines and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland.
J Autoimmun. 2015 Sep;63:68-75. doi: 10.1016/j.jaut.2015.07.006. Epub 2015 Jul 27.
Following the mass vaccinations against pandemic influenza A/H1N1 virus in 2009, a sudden increase in juvenile onset narcolepsy with cataplexy (NC) was detected in several European countries where AS03-adjuvanted Pandemrix vaccine had been used. NC is a chronic neurological disorder characterized by excessive daytime sleepiness and cataplexy. In human NC, the hypocretin-producing neurons in the hypothalamus or the hypocretin signaling pathway are destroyed by an autoimmune reaction. Both genetic (e.g. HLA-DQB10602) and environmental risk factors (e.g. Pandemrix) contribute to the disease development, but the underlying and the mediating immunological mechanisms are largely unknown. Influenza virus hemagglutinin is known to bind gangliosides, which serve as host cell virus receptors. Anti-ganglioside antibodies have previously been linked to various neurological disorders, like the Guillain-Barré syndrome which may develop after infection or vaccination. Because of these links we screened sera of NC patients and controls for IgG anti-ganglioside antibodies against 11 human brain gangliosides (GM1, GM2, GM3, GM4, GD1a, GD1b, GD2, GD3, GT1a, GT1b, GQ1b) and a sulfatide by using a line blot assay. Samples from 173 children and adolescents were analyzed: 48 with Pandemrix-associated NC, 20 with NC without Pandemrix association, 57 Pandemrix-vaccinated and 48 unvaccinated healthy children. We found that patients with Pandemrix-associated NC had more frequently (14.6%) anti-GM3 antibodies than vaccinated healthy controls (3.5%) (P = 0.047). Anti-GM3 antibodies were significantly associated with HLA-DQB10602 (P = 0.016) both in vaccinated NC patients and controls. In general, anti-ganglioside antibodies were more frequent in vaccinated (18.1%) than in unvaccinated (7.3%) individuals (P = 0.035). Our data suggest that autoimmunity against GM3 is a feature of Pandemrix-associated NC and that autoantibodies against gangliosides were induced by Pandemrix vaccination.
在 2009 年大规模接种甲型 H1N1 大流行流感疫苗后,几个使用 AS03 佐剂的潘立酮疫苗的欧洲国家突然发现青少年起病的猝倒性嗜睡症(NC)病例增多。NC 是一种慢性神经系统疾病,其特征是白天过度嗜睡和猝倒。在人类 NC 中,下丘脑产生下丘脑素的神经元或下丘脑素信号通路被自身免疫反应破坏。遗传因素(如 HLA-DQB10602)和环境风险因素(如潘立酮)都有助于疾病的发展,但潜在和介导免疫的机制在很大程度上尚不清楚。流感病毒血凝素已知与神经节苷脂结合,神经节苷脂是宿主细胞的病毒受体。抗神经节苷脂抗体以前与各种神经疾病有关,例如格林-巴利综合征,这种疾病可能在感染或接种疫苗后发展。由于这些联系,我们使用线印迹分析筛选了 NC 患者和对照组的血清中针对 11 个人脑神经节苷脂(GM1、GM2、GM3、GM4、GD1a、GD1b、GD2、GD3、GT1a、GT1b、GQ1b)和神经节苷脂硫酸盐的 IgG 抗神经节苷脂抗体。分析了 173 名儿童和青少年的样本:48 名与潘立酮相关的 NC 患者,20 名与潘立酮无关的 NC 患者,57 名接种潘立酮疫苗的儿童和 48 名未接种疫苗的健康儿童。我们发现,与接种疫苗的健康对照组(3.5%)相比,潘立酮相关 NC 患者更频繁地(14.6%)具有抗 GM3 抗体(P=0.047)。在接种潘立酮的 NC 患者和对照组中,抗 GM3 抗体与 HLA-DQB10602 显著相关(P=0.016)。一般来说,接种疫苗的个体(18.1%)比未接种疫苗的个体(7.3%)更频繁地产生抗神经节苷脂抗体(P=0.035)。我们的数据表明,GM3 的自身免疫是潘立酮相关 NC 的特征,而针对神经节苷脂的自身抗体是由潘立酮疫苗接种诱导的。